Summary Microsatellite instability is a form of genetic damage that may be due to defective mismatch repair genes and may be a marker of processes leading to malignancy. We have analysed a series of epithelial hyperplasia of usual type, carcinomas in situ and invasive and metastatic carcinomas from the mammary gland on the assumption that they represent stages in the evolution of mammary carcinoma. Eight markers on chromosomes 3p, 4q, 9p, 11p, 14q, 17p, 17q and Xq were examined for microsatellite instability and loss of heterozygosity. High rates of loss on chromosomes 17p, 17q and Xq indicate that these chromosomal arms contain genes important in mammary carcinogenesis. The rate of microsatellite instability observed in this study was uniformly low, irrespective of the lesion. This implies that microsatellite instability is not a marker of malignancy in most instances of mammary neoplasia.
Recent studies have focused on the impact of defective mismatch repair (MMR) genes in the pathogenesis of malignancy, particularly in hereditary non-polyposis colorectal carcinoma Bronner et al, 1994; Liu et al, 1994; Nicolaides et al, 1994; Papadopoulos et al, 1994 ; Han et al, 1995) . The theory suggests that cells with defective MMR mechanisms cannot correct genetic errors that occur during cellular replication Parsons et al, 1993 ), e.g. point mutations, deletions, insertions and strand slippage (Loeb, 1994) . Thus, there is a reduction in the fidelity of DNA replication. When errors occur in protooncogenes and anti-oncogenes, loss of control over cell growth and proliferation may develop. Thus, MMR defects have been discussed recently as a mechanism of carcinogenesis equal in importance to primary mutation of proto-oncogenes and antioncogenes (Levine, 1995) .
Microsatellites (also known as short tandem repeats or simple sequence repeats) are sequences of DNA comprising multiple copies of a repeat unit of 1-6 base pairs. They are common, polymorphic and distributed widely throughout the genome. Size instability in microsatellite DNA is associated with certain neurological conditions (Willems, 1994) and has been demonstrated more recently in a variety of malignant neoplasms (e.g. Han et al, 1993; Peltomaki et al, 1993; Horii et al, 1994; Wooster et al, 1994) . There is in vitro evidence that cells with defective MMR genes carry a high frequency of errors in microsatellite sequences (Liu et al, 1995) . Tumours exhibiting microsatellite instability (MSI) are said to have a replication error (RER+) phenotype . In affected carcinomas, the number of repeat units in the microsatellite increases or decreases, although the composition of the unit itself is unaffected (Mironov et al, 1994 ). This instability is demonstrated by comparing DNA from the neoplasm to normal DNA from the same patient. MSI may thus be a marker of defective MMR mechanisms.
The frequency of MSI in mammary carcinomas reported in the literature has generally varied widely. Both Lothe et al (1993) and Peltomaki et al (1993) saw no instances of MSI in the same series of 84 tumours using the same seven microsatellites. Han et al (1993) recorded 1 of 26 (4%) cases exhibiting MSI with four microsatellites; Wooster et al (1994) saw MSI in 11 of 104 (11%) cases of mammary carcinoma when screening with a panel of 12 markers; Yee et al (1994) used seven microsatellites against 20 breast neoplasms and found instability in 4 of 20 (20%); and Huang et al (1995) demonstrated instability in 9 of 29 (31%) tumours with a series of 10 microsatellite markers. At extreme odds with the other reports, Patel et al (1994) detected instability in 11 of 13 (85%) tumours using nine microsatellites. In the total of these series, MSI has been observed in only 36 of 276 (13%) mammary neoplasms. The actual number of instances of instability was only 64 out of 2499 (2.5%) but ranged from 0% Peltomaki et al, 1993) to 34% (Patel et al, 1994) . The number of instances of MSI reported was below 1% in four of the seven studies mentioned above and less than or equal to 6% for six of the seven studies. The greatest problem when comparing the different series is the fact that each group generally uses a different set of microsatellite markers, thus making true comparison impossible.
While MSI has been studied in a variety of malignant neoplasms, its timing in carcinogenesis has not been systematically investigated. Assuming that it plays a role in some instances, the timing of MSI in carcinogenesis may pinpoint its role either in the initiation of carcinogenesis or in events that determine subsequent progression. We consequently investigated the occurrence of MSI in epithelial hyperplasia of usual type and in situ, invasive and metastatic carcinomas of the mammary gland on the assumption that the lesions represent stages in the evolution of malignant neoplasia. lymph node metastases and one a muscle metastasis). In total, 164 specimens from 120 patients were analysed. All DNA was extracted from the paraffin-embedded tissues by methods described elsewhere (Turbett et al, 1996) . Normal tissue and either two or three lesional types from the same patient were obtained in 26 cases. There were two cases in which DNA was obtained from normal tissue as well as samples of epithelial hyperplasia, carcinoma in situ, invasive carcinoma and metastatic tumour from the same patient. Of the 18 epithelial hyperplasia specimens, normal tissue and one or more other lesional type was obtained in 11 instances. The microsatellite loci analysed included three tetranucleotides, three trinucleotides and two dinucleotides ( Table 1) . Some of the microsatellites were specifically chosen to represent chromosomes known to be associated with breast malignancy, while others were used because those chromosomal areas were not known to be involved. The amplification buffer was 67 mm Tris-HCl (pH 8.8), 16.6 mm ammonium sulphate, 0.45% Triton X-100, 0.2 mg ml-' gelatin, 0.2 mm dNTPs, 0.1 JIM of each primer, 1-4 mM magnesium chloride, 1 ,uCi [a-32P] dCTP (Redivue; Amersham, NSW, Australia) and 0.5 units of Taq DNA polymerase per 25-,ul reaction.
Amplifications were performed on an MJ Research PTC-100 thermal cycler fitted with a hot bonnet (Watertown, MA, USA). Typical thermocycle conditions were 94°C for 1 min, 50-60'C for 1 min and 72°C for 1 min, for a total of 35 cycles. The initial denaturation and final extension steps were extended to 5 min.
The tri-and tetranucleotide markers were analysed by electrophoresis of the PCR products on 8-10% 20-cm polyacrylamide gels at 8-12 mA constant current for 12-15 h. This was followed by silver staining using the method of Bassam et al (1991) . The dinucleotide markers and all cases of MSI found in silver-stained gels were analysed on 6% polyacrylamide, 7 M urea, 40-cm polyacrylamide gels and subsequent autoradiography.
Every case was tested at seven of the loci, but there was insufficient DNA to test all samples at the THOl locus. Results were scored by visual examination of the autoradiograph. MSI was considered to have occurred if either allele in the tumour sample showed altered electrophoretic mobility or if novel alleles were present in the tumour sample in comparison with the normal. Allelic loss was scored by visual examination of the autoradiographs, and loss of heterozygosity (LOH) in tumour specimens was considered to have occurred if there was a significant alteration in the relative allele intensities between the two alleles for the tumour sample compared with those from the normal sample. Cases in which the lesional DNA was different to the normal were counted as either MSI or LOH but not both; when both LOH and MSI was seen, the result was scored as MSI only (for example, see sample 18 at the HUMARA locus in Figure 1 ).
RESULTS
Of the 1274 instances tested, 1115 (88%) produced a result (homozygous, heterozygous, LOH or MSI). All instances producing a result were informative for the occurrence of MSI.
Instances showing MSI and homozygosity were not informative for LOH. Tables 2 and 3 show the results of testing at each locus for each lesion type. In epithelial hyperplasia, only one instance of MSI was observed out of a total of 112, giving an overall incidence of 0.9%. In the carcinomas in situ, there was only one occurrence of MSI, at the FABP locus, giving a total occurrence of 0.6%. In the invasive carcinomas, MSI was observed at all eight loci examined. The highest rate was seen at the D3S 1514 locus, with 4 of 94 (4.3%) cases exhibiting MSI. There were two occurrences at each of D9S254 and HUMARA and one occurrence at each of the remaining five loci. The total rate of MSI in the invasive carcinomas was 13 out of 733 (1.8%), which was the highest rate seen. There were no instances of MSI seen at any locus in the metastatic breast carcinomas, although the number of cases analysed was small. Of the 120 patients examined, the occurrence of MSI at one or more loci in any lesion type was seen in only 13 patients, giving an overall occurrence of MSI in breast cancer patients of 10.8%. Overall, there were 15 occurrences of MSI seen in the 13 patients, with only one case (0.83% of all cases) showing MSI at more than one locus. This was a medullary carcinoma, which exhibited MSI at three loci: D3S1514, D9S254 and D17S855 ( Figure 1 ).
Both expansion (larger allele) and contraction (smaller allele) instabilities were observed, although contractions were far more common (14 of 18 novel alleles). The three expansion instabilities seen were for D3S1514, SCA3 and HUMARA. Other examples of cases showing MSI are presented in Figure 1 . Tumour 18 shows a simple contraction instability, while tumours 37 and 38 exhibit complex instabilities. Tumour 37 shows two novel contracted alleles. One of the novel alleles present in tumour 38 is an expansion, while the other cannot be classified as either. Because it is present in the tumour sample at a molecular size intermediate to the two original alleles, there is no way to determine whether it represents an expansion of the lower normal allele or a contraction of the upper normal allele. A summary of the types of instabilities observed are provided in Table 4 . Overall, the rate of observed instability decreased as the size of the repeat unit decreased. From the results in Table 2 , it may be seen that the overall rate of instability was 8 out of 407 (2.0%) for the tetranucleotides, 5 out of 404 (1.2%) for the trinucleotides and 2 out of 304 (0.66%) for the dinucleotides.
Of the 120 patients from whom samples were taken, LOH of at least one of the eight loci was observed in 65 (54.2%). Of (1993) showed a clear preference for expansions rather than contractions, with 77.5% of instabilities presenting as a larger allele. In contrast, most instabilities observed in this study were contractions, with only 3 of 13 (23%) expansion instabilities seen. The reason for this discrepancy is unknown. The observation that the rate of instability was three times greater in the tetranucleotides (2.0%) than in the dinucleotides (0.66%) has been reported previously (Weber and Wong, 1993; Mao et al, 1994) . It would be worthwhile to investigate mononucleotide and pentanucleotide repeats to see whether this pattern continued. The reason for this variation in the rate of MSI between repeat types is unknown; although Weber and Wong (1993) have suggested that the discrepancy may be artefactual because of the under-reporting of instances of MSI in dinucleotides due to the masking of novel alleles by the strand slippage products common to dinucleotide repeats. If this was the case, then one would not expect to see a difference in the rate of instability between trinucleotides and tetranucleotides, assuming a common mechanism for the development of instability.
The fact that tetranucleotides appear to exhibit a greater rate of instability than dinucleotides means that the results obtained in any investigation screening for MSI will be highly dependent upon the type of repeats chosen. A study using tetranucleotides would be expected to find an incidence of MSI three times greater than another study using dinucleotides. Furthermore, there is now evidence that in particular tumour types, different microsatellite loci are inherently more likely to show instability than other loci with the same repeat length. Mao et al (1996) have described a method for detection of primary bladder cancers by microsatellite analysis. They screened a series of 60 tri-and tetranucleotide markers against 50 primary bladder cancers. They were able to rank the markers according to their susceptibility to alteration and select a panel of the 10 best microsatellite loci to use when screening for bladder cancers. Their results would suggest that, at least in bladder cancer, the rate of instability varies between microsatellites. It would be useful to determine whether the increased rates of instability seen in certain microsatellite loci are specific to a particular tumour type (tumour-specific instability) or whether these loci are generally prone to instability, regardless of the type of tumour (general tumour instability).
A problem with defining the percentage of tumours in a given study that show the RER+ phenotype is that an accurate definition of what constitutes RER+ does not appear to be documented. It would be of great value if all researchers could agree upon a specific panel of microsatellite markers for the screening of tumours for the presence of MSI. This would make comparisons between research groups, different tumours and different tumour types possible. Until such uniformity is achieved, direct comparisons of the results obtained by different research groups is impossible and can lead to wildly different estimates of the rate of MSI in a given tumour type Peltomaki et al, 1993; Patel et al, 1994) . If the presence of any MSI is assumed to be indicative of an RER+ phenotype, then the rate of RER+ tumours seen in this study was 10.8%, similar to that reported by Wooster et al (1994) .
There are no universal sites of genetic damage known to occur in mammary carcinoma. The background (random) rate of LOH in the mammary gland has been reported as 4% (Chen et al, 1992) , and previous reports suggest a frequency of LOH at certain sites in invasive carcinoma of 19-60% (Callahan and Campbell, 1989; Ben Cheickh et al, 1992; Mooi and Peterse, 1992; Takita et al, 1992) . While the D3S1514 (3p2l-pl4.2; Buchhagen et al, 1994) , D9S254 (9p23-p2l; Brenner and Aldaz, 1995) and THOI (lpIS.5; Winqvist et al, 1993; Gudmundsson et al, 1995) loci have been reported to be important in breast carcinogenesis, the FABP and SCA3 loci were chosen as being representative of chromosomal regions thought to be irrelevant to mammary carcinogenesis. In the invasive carcinomas studied here, a similarly low rate of LOH (9.1-13%) was observed at the D3S1514, FABP, D9S254, THOI and SCA3 loci, which is two to three times the background rate reported by Chen et al (1992) . The reason for this is unknown. The remaining three loci showed high rates of LOH (24-38%), suggesting that genes on chromosomes 17p, 17q and Xq may be important in the development of invasive mammary carcinoma.
It has been previously reported that invasive carcinomas showing LOH at lp are more likely to metastasize (Takita et al, 1992) . Our study showed that LOH at this site occurred concurrently with the development of invasive carcinoma, and an even higher rate of LOH was observed in metastases (Table 3 ). This suggests that LOH at this site may be associated with the acquisition of an invasive phenotype and the ability to metastasize. On chromosome 9p, LOH has previously been reported in 58% of invasive carcinomas (Brenner and Aldaz, 1995) , but this study found LOH in only 11% of instances, and no instances of loss were seen in the metastatic tumours. LOH on both arms of chromosome 17 and on Xq occurred concurrently with histological features of carcinoma in situ and were present at a greater rate in invasive carcinoma. The rate of loss for all three loci was actually seen to decrease in the metastatic tumours, particularly the two chromosome 17 loci. LOH events at these sites may therefore have a role in the expression of morphological or invasive characteristics but not necessarily in the development of metastases.
There were significant associations between LOH of markers on both arms of chromosome 17 in all tissue grades (Table 5) , which suggests that allelic loss at these sites may be separate but associated events. It is also possible that the entire chromosome 17 is deleted -study of additional chromosome 17 markers would confirm the loss of the entire chromosome. We studied the D17S855 microsatellite located within the BRCAJ gene, whose mutation is associated with the development of familial mammary carcinoma occurring at an early age (Chan, 1995) . Loss of heterozygosity at D17S855 suggests deletion of all or part of the gene. To date, the timings of BRCAJ mutations and losses of heterozygosity in mammary carcinogenesis have not been studied. We observed one instance of loss at D17S855 in eleven epithelial hyperplasias, 22% loss in carcinoma in situ and a 32% rate of loss in invasive carcinomas; in metastatic carcinomas, the rate of loss decreased to 18%. Our data imply that LOH of BRCAJ may be an event that occurs early in mammary carcinogenesis (around the stage of carcinoma in situ) and may also be observed in some epithelial hyperplasias. In patient 80, samples of epithelial hyperplasia, carcinoma in situ and invasive ductal carcinoma were analysed. Loss at the D17S855 locus was observed in the carcinoma in situ and the invasive tumour DNA but not in the epithelial hyperplasia. A high rate of LOH on 17q in invasive carcinoma and the fact that only 1-2% of mammary carcinomas carry detectable mutation in the BRCAJ gene (Chan, 1995) implies the presence of other genes in the region that may have a role in mammary carcinogenesis. Cropp et al (1993) have identified three discrete regions of chromosome 17q that are frequently deleted in mammary carcinomas.
Despite a high frequency of LOH of D17S559 on 17p, there was no correlation with mutation in exons 5-9 of the p53 gene (unpublished data) located on this arm (P = 0.0683 using Fisher's exact test), a finding supported by that of Deng et al (1994) . Other workers have noted that, in 60% of breast carcinomas showing LOH at the p53 site, the retained allele is native, i.e. not mutated (Moll et al, 1992) . This implies that there may be other target sites on this chromosome arm (Sato et al, 1991) .
LOH at 3p showed a statistically significant association with mutations in exons 5-9 of p53 (P = 0.0148 using Fisher's exact test), which is located on chromosome 17p. This has been previously reported by Deng et al (1994) . There were also significant associations between LOH on chromosomes 3p and 17p (P = 0.0193 for invasive carcinoma alone; P = 0.0151 for hyperplasia, carcinoma in situ, invasive and metastatic carcinoma). A major role of p53 is to act as a checkpoint factor by halting cell replication unless the genome is intact. Therefore, loss of normal p53 activity might allow persistence of errors in genes located on 3p. It is also possible that mutations in p53 occur after LOH on 3p, particularly as chromosome 3p carries the DNA mismatch repair gene hMLHJ. LOH at this site might result in a down-grading of the cell's ability to repair errors of replication.
When the rates of LOH seen in all cases with MSI was compared with the rates of LOH in all cases without MSI, there were no apparent differences. Of the 13 cases that showed MSI, seven (53.8%) showed no loss, while 82 of 151 (54.3%) cases without MSI also showed no evidence of LOH. In the remaining six cases with MSI, there were 13 occurrences of LOH. The number of occurrences of loss at each locus was as follows: D3S1514 (two), FABP (one), D9S254 (zero), THOI (one), SCA3 (two), D17S559 (three), D17S855 (three) and HUMARA (one). The only case that showed LOH at five of the eight loci tested also showed MSI, while the single case that showed more than one instance of MSI showed no LOH. Thus, there was no obvious association between the occurrence of LOH and MSI within samples.
Overall, the occurrence of any microsatellite alteration was 33% in the epithelial hyperplasias and 32% in the carcinomas in situ, but this almost doubled to 65% in the invasive tumours. Aldaz et al (1995) reported that 74% of 23 ductal carcinomas in situ showed at least one alteration in a panel of 20 microsatellite markers. The reason for the discrepancy between their results and those obtained here may be attributed to the larger number of microsatellite markers they used, as well as the locations of those markers. The number of metastatic tumours analysed in this study that showed at least one alteration was 46%, lower than for the invasive tumours. The reason for this is unknown. The rates of LOH reported by Aldaz et al (1995) for the ductal carcinomas in situ are in close agreement with the results obtained in this study. They reported no losses at 3p or l Ip and high rates (25-30%) of loss at 17p and 17q. We saw no LOH at 3p or lIp and a rate of LOH of 24% at 17p and 22% at 17q.
The findings of this investigation suggest that, unlike hereditary non-polyposis colorectal carcinoma, the RER+ phenotype is uncommon, and MSI does not play a significant role in the initiation or progression of most instances of mammary carcinomas. We did not observe a significant occurrence of MSI in the tumours examined. MSI was seen in epithelial hyperplasias, carcinomas in situ and invasive carcinomas, but the rate of instability observed did not alter. This would indicate that the MSI seen in most mammary neoplasms is some form of epiphenomenon that is of neutral effect, not providing the tumour with either a selective growth advantage or disadvantage. In contrast, LOH was a more common phenomenon than MSI in all tissues studied, indicating that it may be an important mechanism in the pathogenesis of breast cancer.
